Zanamivir CAS NO 139110-80-8 Inquire about Zanamivir

Tecoland supplies Zanamivir bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Zanamivir is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Zanamivir?

Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza Aand B viruses. In 2006, it was approved for prevention of influenza A and B.  Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.

What is Zanamivir used for?

Zanamivir is used for the treatment of infections caused by influenza A and influenza B viruses, but in otherwise-healthy individuals, benefits overall appear to be small. It decreases the risk of one’s getting symptomatic, but not asymptomatic influenza. The combination of diagnostic uncertainty, the risk for virus strain resistance, possible side effects and financial cost outweigh the small benefits of zanamivir for the prophylaxis and treatment of healthy individuals. As of 2009, no influenza has shown any signs of resistance in the US. Since then, genes expressing resistance to zanamivir were found in Chinese people infected with avian influenza A H7N9 during treatment with zanamivir.

Mechanism of action

Zanamivir works by binding to the active site of the neuraminidase protein, rendering the influenza virus unable to escape its host cell and infect others. It is also an inhibitor of influenza virus replication in vitro and in vivo. In clinical trials, zanamivir was found to reduce the time-to-symptom resolution by 1.5 days if therapy was started within 48 hours of the onset of symptoms.

The bioavailability of zanamivir is 2%. After inhalation, zanamivir is concentrated in the lungs and oropharynx, where up to 15% of the dose is absorbed and excreted in urine.

Side Effects

Dosing is limited to the inhalation route. This restricts its usage, as treating asthmatics could induce bronchospasms.